Risk of FFN receipt by LTC stratified by age group
| LTC; by age in years | N (%) 326 415 | N people with FFN since 2014 | Rate FFN per 1000 | HR*(95% CI) | Adjusted hazard ratio (95% CI)† | PAF§ |
| No LTC | 212 436 (65.1) | 16 647 (7.8) | 39.1 | 1 | 1 | 0.0% |
| 16–40 | 172 445 (72.9) | 11 903 (6.9) | 36.1 | 1 | 1 | 0.0% |
| 41–50 | 28 130 (50.3) | 3136 (11.2) | 46.9 | 1 | 1 | 0.0% |
| 51–60 | 11 861 (35.0) | 1608 (13.6) | 56.0 | 1 | 1 | 0.0% |
| Depression | 33 477 (10.3) | 10 271 (30.7) | 155.8 | 3.9 (3.7 to 4.1) | 3.4 (3.3 to 3.6) | 17.5% |
| 16–40 | 19 312 (8.2) | 5060 (26.2) | 141.3 | 3.8 (3.7 to 4.0) | 3.6 (3.5 to 3.8) | 15.3% |
| 41–50 | 8312 (14.9) | 2965 (35.7) | 168 | 3.5 (3.3 to 3.7) | 3.3 (3.1 to 3.5) | 19.6% |
| 51–60 | 5853 (17.2) | 2246 (38.4) | 179.7 | 3.1 (2.8 to 3.3) | 2.9 (2.7 to 3.2) | 18.2% |
| Cancer | 3557 (1.1) | 1138 (32.0) | 150.5 | 3.8 (3.4 to 4.2) | 3.0 (2.7 to 3.3) | 1.8% |
| 16–40 | 1050 (0.4) | 231 (22.0) | 110.8 | 3.0 (2.6 to 3.5) | 3.1 (2.7 to 3.5) | 0.7% |
| 41–50 | 998 (1.8) | 386 (38.7) | 182.4 | 3.8 (3.3 to 4.4) | 3.5 (3.1 to 4.0) | 2.6% |
| 51–60 | 1509 (4.5) | 521 (34.5) | 155 | 2.7 (2.4 to 3.0) | 2.5 (2.2 to 2.9) | 3.9% |
| Obesity | 49 847 (15.3) | 11 821 (23.7) | 108.6 | 2.7 (2.5 to 2.9) | 2.1 (2.0 to 2.2) | 14.9% |
| 16–40 | 23 396 (9.9) | 4356 (18.6) | 90.3 | 2.5 (2.3 to 2.7) | 2.0 (1.9 to 2.2) | 9.1% |
| 41–50 | 14 594 (26.1) | 3915 (26.8) | 117.4 | 2.5 (2.3 to 2.7) | 2.1 (2.0 to 2.2) | 19.4% |
| 51–60 | 11 857 (34.9) | 3550 (29.9) | 130.3 | 2.3 (2.1 to 2.5) | 2.1 (1.9 to 2.2) | 23.0% |
| Diabetes‡ | 9.946 (3.1) | 2830 (28.5) | 128.8 | 3.2 (2.9 to 3.6) | 2.2 (2.1 to 2.4) | 3.7% |
| 16–40 | 2036 (0.9) | 408 (20.0) | 101.6 | 2.8 (2.5 to 3.1) | 2.4 (2.1 to 2.7) | 1.0% |
| 41–50 | 3258 (5.8) | 940 (28.9) | 126.6 | 2.7 (2.4 to 3.0) | 2.2 (2.0 to 2.5) | 4.9% |
| 51–60 | 4652 (13.7) | 1482 (31.9) | 140.6 | 2.5 (2.2 to 2.7) | 2.3 (2.1 to 2.5) | 10.4% |
| SMI | 4598 (1.4) | 1227 (26.7) | 126.8 | 3.2 (2.9 to 3.5) | 2.4 (2.2 to 2.6) | 1.7% |
| 16–40 | 2169 (0.9) | 615 (28.4) | 154.1 | 4.2 (3.8 to 4.7) | 3.3 (3.0 to 3.7) | 1.8% |
| 41–50 | 1357 (2.4) | 376 (27.7) | 122.6 | 2.6 (2.3 to 3.0) | 2.1 (1.9 to 2.4) | 1.9% |
| 51–60 | 1072 (3.2) | 236 (22.0) | 90.1 | 1.6 (1.4 to 1.9) | 1.4 (1.2 to 1.7) | 0.8% |
| Cardio | 1144 (0.4) | 379 (31.4) | 147.6 | 3.7 (3.3 to 4.2) | 2.8 (2.5 to 3.3) | 0.6% |
| 16–40 | 211 (0.1) | 49 (23.2) | 117.3 | 3.2 (2.4 to 4.3) | 2.8 (2.1 to 3.7) | 0.1% |
| 41–50 | 331 (0.6) | 117 (35.4) | 175.8 | 3.7 (3.0 to 4.5) | 3.3 (2.7 to 4.1) | 0.8% |
| 51–60 | 602 (1.8) | 193 (32.1) | 143.1 | 2.5 (2.1 to 3.0) | 2.5 (2.1 to 3.0) | 1.4% |
| Vascular | 1474 (0.5) | 534 (36.2) | 172.5 | 4.3 (3.9 to 4.8) | 3.0 (2.7 to 3.4) | 0.9% |
| 16–40 | 203 (0.1) | 62 (30.5) | 151.1 | 4.1 (3.1 to 5.5) | 3.4 (2.5 to 4.6) | 0.2% |
| 41–50 | 408 (0.7) | 169 (41.4) | 212.6 | 4.4 (3.7 to 5.3) | 3.7 (3.0 to 4.5) | 1.2% |
| 51–60 | 863 (2.5) | 303 (35.1) | 160.2 | 2.8 (2.4 to 3.2) | 2.6 (2.3 to 3.0) | 2.5% |
| Respiratory | 35 153 (10.8) | 6156 (17.5) | 85.0 | 2.2 (2.1 to 2.3) | 2.0 (1.9 to 2.0) | 7.4% |
| 16–40 | 25 188 (10.7) | 3214 (12.8) | 65.0 | 1.8 (1.7 to 1.9) | 1.7 (1.7 to 1.8) | 5.5% |
| 41–50 | 5828 (10.4) | 1566 (26.9) | 116.4 | 2.4 (2.3 to 2.6) | 2.3 (2.1 to 2.4) | 8.4% |
| 51–60 | 4137 (12.2) | 1376 (33.3) | 147.4 | 2.6 (2.3 to 2.8) | 2.3 (2.1 to 2.5) | 9.6% |
| Chronic pain | 4550 (1.4) | 1870 (41.1) | 201.3 | 5.0 (4.5 to 5.5) | 3.7 (3.3 to 4.0) | 3.3% |
| 16–40 | 990 (0.4) | 412 (41.6) | 221.1 | 6.0 (5.2 to 6.8) | 4.8 (4.3 to 5.5) | 1.4% |
| 41–50 | 1568 (2.8) | 671 (42.8) | 212.3 | 4.4 (3.9 to 4.9) | 3.7 (3.4 to 4.1) | 4.6% |
| 51–60 | 1992 (5.9) | 787 (39.5) | 184.4 | 3.2 (2.8 to 3.6) | 2.9 (2.6 to 3.3) | 6.4% |
| LD | 839 (0.3) | 170 (20.3) | 81.4 | 2.1 (1.6 to 2.6) | 1.5 (1.2 to 1.8) | 0.1% |
| 16–40 | 432 (0.2) | 92 (21.3) | 89.0 | 2.4 (1.9 to 3.2) | 1.8 (1.4 to 2.4) | 0.2% |
| 41–50 | 229 (0.4) | 48 (21.0) | 84.1 | 1.8 (1.3 to 2.4) | 1.4 (1.0 to 1.8) | 0.1% |
| 51–60 | 178 (0.5) | 30 (16.9) | 62.1 | 1.1 (0.8 to 1.5) | 1.0 (0.7 to 1.3) | 0.0% |
| Epilepsy | 2298 (0.7) | 574 (25.0) | 117.9 | 3.0 (2.7 to 3.3) | 2.6 (2.3 to 2.9) | 0.9% |
| 16–40 | 1254 (0.5) | 266 (21.2) | 107.3 | 2.9 (2.6 to 3.3) | 2.8 (2.5 to 3.2) | 0.7% |
| 41–50 | 583 (1.0) | 170 (29.2) | 130.5 | 2.7 (2.3 to 3.3) | 2.5 (2.0 to 3.0) | 1.0% |
| 51–60 | 461 (1.4) | 138 (29.9) | 127.3 | 2.2 (1.9 to 2.7) | 2.2 (1.8 to 2.6) | 0.9% |
| RA | 827 (0.3) | 258 (31.2) | 146.5 | 3.7 (3.3 to 4.1) | 2.6 (2.3 to 3.0) | 0.4% |
| 16–40 | 257 (0.1) | 58 (22.6) | 111.6 | 3.1 (2.4 to 4.0) | 2.6 (2.0 to 3.5) | 0.2% |
| 41–50 | 243 (0.4) | 79 (32.5) | 148.5 | 3.1 (2.5 to 3.9) | 2.7 (2.1 to 3.4) | 0.5% |
| 51–60 | 327 (1.0) | 121 (37.0) | 170.6 | 3.0 (2.4 to 3.7) | 2.6 (2.0 to 3.2) | 0.9% |
| Hypertension | 18 190 (5.6) | 5400 (29.7) | 131.6 | 3.3 (3.1 to 3.5) | 2.2 (2.1 to 2.4) | 7.1% |
| 16–40 | 2765 (1.2) | 642 (23.2) | 110.1 | 3.0 (2.7 to 3.3) | 2.3 (2.2 to 2.5) | 1.5% |
| 41–50 | 6270 (11.2) | 1867 (29.8) | 130.7 | 2.8 (2.5 to 3.0) | 2.2 (2.1 to 2.4) | 9.6% |
| 51–60 | 9155 (27.0) | 2891 (31.6) | 138.2 | 2.4 (2.2 to 2.6) | 2.2 (2.0 to 2.4) | 19.5% |
*Hazard ratios estimate a ratio of time to FFN for groups with a LTC compared with the group with no LTC.
†Adjusted for age, sex, ethnicity and deprivation.
‡Diabetes type 2;
§PAF estimates the proportion of the incidence of fit note receipt that is potentially attributable to having the LTC.
Cardio, coronary heart disease, atrial fibrillation and heart failure; FFN, first fit note; LD, disability; LTC, long-term condition; PAF, population attributable fraction; RA, rheumatoid arthritis; SMI, serious mental illness; Vascular, peripheral arterial disease, stroke and transient ischaemia.